CytomX Therapeutics (CTMX) EBT Margin (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly EBT Margin came in at 177.32% in Q1 2026, down 22364.0% YoY from N/an in Q1 2025, and up 95.56% on a QoQ basis from 3990.35% in Q4 2025.
CytomX Therapeutics (CTMX) EBT Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of EBT Margin data on file, last reported at 177.32% in Q1 2026.
- Quarterly EBT Margin fell 22364.0% year-over-year to 177.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 165.74% (down 19409.0% YoY) and the FY2025 annual result came in at 22.48%, down 4572.0% from the prior year.
- EBT Margin grew to 177.32% in Q1 2026, from 3990.35% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 49.72% in Q4 2024 to a low of 3990.35% in Q4 2025.
- A 5-year average of 303.63% and a median of 14.09% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin jumped 33968 bps — and 2025, when it sank 404006 bps.
- Tracing CTMX's EBT Margin over 5 years: stood at 43.61% in 2022, then soared by 116 bps to 7.16% in 2023, then soared by 594 bps to 49.72% in 2024, then slumped by 8126 bps to 3990.35% in 2025, then surged by 96 bps to 177.32% in 2026.
- The last three EBT Margin figures came in at 177.32% (Q1 2026), 3990.35% (Q4 2025), and 237.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -1,453.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,453.17% |
| Mar 31, 2026 | -177.32% |
| Dec 31, 2025 | -3,990.35% |
| Sep 30, 2025 | -237.65% |
| Jun 30, 2025 | -0.49% |
| Mar 31, 2025 | 46.32% |
| Dec 31, 2024 | 49.72% |
| Sep 30, 2024 | 17.34% |
| Jun 30, 2024 | -25.81% |
| Mar 31, 2024 | 33.38% |
| Dec 31, 2023 | 7.16% |
| Sep 30, 2023 | 22.04% |
| Jun 30, 2023 | -4.40% |
| Mar 31, 2023 | -14.09% |
| Dec 31, 2022 | -43.61% |
| Sep 30, 2022 | -260.73% |
| Jun 30, 2022 | -229.49% |
| Mar 31, 2022 | -353.77% |
| Dec 31, 2021 | -312.82% |
| Sep 30, 2021 | -337.16% |